The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover

Bay‐Jensen, Anne‐Christine; Tabassi, N. Charni-Ben; Søndergaard, Lene Vammen; Andersen, Thomas Levin; Dagnæs‐Hansen, Frederik; Garnero, Patrick; Kassem, Moustapha; Delaissé, Jean‐Marie

doi:10.1186/ar2596

Cited by 34 publications

(22 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estrogen receptors (ERs) have been identified in articular chondrocytes in animals and humans, and estrogen can elicit genomic and nongenomic effects on the regulation of cartilage metabolism (85,86). The effects of estrogen administration on the development and severity of osteoarthritis remain controversial, despite multiple epidemiological, clinical, and experimental studies (87)(88)(89)(90).…”

Section: Degenerative Arthritismentioning

confidence: 99%

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

Santen

Allred

Ardoin

et al. 2010

The Journal of Clinical Endocrinology & Metabolism

566

365

View full text Add to dashboard Cite

The major conclusions related to the overall benefits and risks of MHT expressed as the number of women per 1000 taking MHT for 5 yr who would experience benefit or harm. Primary areas of benefit included relief of hot flashes and symptoms of urogenital atrophy and prevention of fractures and diabetes. Risks included venothrombotic episodes, stroke, and cholecystitis. In the subgroup of women starting MHT between ages 50 and 59 or less than 10 yr after onset of menopause, congruent trends suggested additional benefit including reduction of overall mortality and coronary artery disease. In this subgroup, estrogen plus some progestogens increased the risk of breast cancer, whereas estrogen alone did not. Beneficial effects on colorectal and endometrial cancer and harmful effects on ovarian cancer occurred but affected only a small number of women. Data from the various Women's Health Initiative studies, which involved women of average age 63, cannot be appropriately applied to calculate risks and benefits of MHT in women starting shortly after menopause. At the present time, assessments of benefit and risk in these younger women are based on lower levels of evidence.

show abstract

Section: Degenerative Arthritismentioning

confidence: 99%

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

Santen

Allred

Ardoin

et al. 2010

The Journal of Clinical Endocrinology & Metabolism

566

365

View full text Add to dashboard Cite

show abstract

“…The α1(III) sequence, ERGETGPP*GPA, is identical to that of α1(II), so neither α1(II), α1(I) nor α1(III) can be the source of the inhibition at least from peptides originating at this helical locus. Rat type II collagen has the same sequence, ERGETGPPGPA, as human, so the Helix-II assay results reported for experimental rats12 have a similar problem.…”

Section: Resultsmentioning

confidence: 96%

“…Clearly human urine and serum give an inhibitory signal and statistically significant differences are evident between patients and control subjects in several clinical studies4,6-8. The Helix-II epitope can also be generated from human cartilage in vitro by cathepsin digestion10, shows diurnal variability in urinary excretion11 and no response to estrogen in post-menopausal women or experimental rats12.…”

Section: Resultsmentioning

confidence: 99%

The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence

Eyre

Weis

2009

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

Summary Objective An apparent database error in the sequence underlying the Helix-II cartilage biomarker immunoassay was investigated at the protein level. Methods and Results Tandem mass spectrometry established the peptide sequence ERGETGPP*GPA in human type II collagen, not ERGETGPP*GTS used to generate the antibody for the Helix-II assay. Conclusions Recent reports in which the Helix-II assay was applied to urine or serum as a marker of cartilage collagen degradation need to be re-evaluated since the epitope does not occur in cartilage type II collagen. Based on collagen sequences and Helix-II epitope properties, type III collagen is one of several candidate sources of the cross-reacting signal in body fluids, but not type II collagen. The findings highlight the need for more stringent scrutiny of the origins and validation of molecular markers in body fluid assays in general.

show abstract

“…No association has been found for urinary Helix II and estrogen deprivation leading to cartilage breakdown 96 . Study of 860 women in China noted that menopause is associated with cartilage degeneration of knee joint compared to pre and peri-menopausal women.…”

Section: Osteoarthritismentioning

confidence: 99%

Menopause and Rheumatic Disease

Talsania

Scofield

2017

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Abstract/Synopsis Menopause occurs naturally in women at about age 50. There is a wealth of data concerning the relationship of menopause to systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis, while there are limited data concerning other rheumatic diseases. Age at menopause may affect the risk and course of rheumatic diseases. Osteoporosis, an integral part of inflammatory rheumatic diseases, is made worse by menopause. Hormone replacement therapy has been studied and its effects are varied depending upon the disease and even different manifestations within the same disease. Cyclophosphamide can induce early menopause but there is underlying decreased ovarian reserve in rheumatic diseases.

show abstract

The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover

Cited by 34 publications

References 47 publications

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence

Menopause and Rheumatic Disease

Contact Info

Product

Resources

About